{
    "clinical_study": {
        "@rank": "137822", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)"
            }, 
            {
                "arm_group_label": "Brexpiprazole", 
                "arm_group_type": "Experimental", 
                "description": "Brexpiprazole adjunct to open-label treatment with a commercially available ADT"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the maintenance of efficacy and safety during long-term treatment with\n      brexpiprazole as an adjunctive treatment for adult subjects with Major Depressive Disorder\n      (MDD)"
        }, 
        "brief_title": "Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment", 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The patient is an outpatient consulting a psychiatrist.\n\n          -  The patient has an MDD diagnosed according to DSM-IV-TR\u2122. The current Major\n             Depressive Episode (MDE) should be confirmed using the Mini International\n             Neuropsychiatric Interview (MINI).\n\n          -  The patient has a moderate to severe depression and an insufficient response to at\n             least one and no more than three adequate antidepressant treatments.\n\n          -  The patient agrees to protocol-defined use of effective contraception.\n\n        Exclusion Criteria:\n\n          -  The patient has any current psychiatric disorder or Axis I disorder (DSM-IV-TR\u2122\n             criteria), established as the primary diagnosis, other than MDD.\n\n          -  The patient has a current Axis II (DSM-IV-TR\u2122) diagnosis of borderline, antisocial,\n             paranoid, schizoid, schizotypical or histrionic personality disorder.\n\n          -  The patient has experienced/experiences hallucinations, delusions or any psychotic\n             symptomatology in the current MDE.\n\n          -  The patient suffers from mental retardation, organic mental disorders, or mental\n             disorders due to a general medical condition (DSM-IV-TR\u2122 criteria).\n\n          -  The patient, in the opinion of the investigator or according to Columbia-Suicide\n             Severity Rating Scale (C-SSRS), is at significant risk of suicide.\n\n          -  The patient has had neuroleptic malignant syndrome.\n\n          -  The patient has any relevant medical history or current presence of systemic disease.\n\n          -  The patient has, at the Screening Visit an abnormal ECG that is, in the\n             investigator's opinion, clinically significant.\n\n          -  The patient has a history of cancer, other than basal cell or Stage 1 squamous cell\n             carcinoma of the skin, that has not been in remission for >5 years prior to the first\n             dose of IMP.\n\n          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol\n             or is unsuitable for any reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1462", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01838681", 
            "org_study_id": "14570A", 
            "secondary_id": "2012-001380-76"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Once daily, tablets, orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Brexpiprazole", 
                "description": "Up to 3 mg/day, once daily dose, tablets, orally", 
                "intervention_name": "Brexpiprazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antidepressive Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kuopio", 
                    "country": "Finland", 
                    "zip": "70110"
                }, 
                "name": "FI001"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Long-term Study to Evaluate the Maintenance of Efficacy and Safety of 1 to 3 mg/Day of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Bulgaria: Bulgarian Drug Agency", 
                "Estonia: The State Agency of Medicine", 
                "Finland: Finnish Medicines Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Latvia: State Agency of Medicines", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Mexico: Federal Commission for Sanitary Risks Protection", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Sweden: Medical Products Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A pre-specified length of remission based on Montgomery and \u00c5sberg Depression Rating Scale (MADRS) total score", 
            "measure": "Full remission during the randomised treatment period", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 36 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01838681"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "A pre-specified length of remission based on Sheehan Disability Scale (SDS) total score", 
                "measure": "Full functional remission during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "A pre-specified length of remission based on Clinical Global Impression - Severity of Illness (CGI-S) score", 
                "measure": "Full global score remission in global clinical impression during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "MADRS total score", 
                "measure": "Change from randomisation in depressive symptoms during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "Based on pre-specified decrease in MADRS total score", 
                "measure": "Response during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "Based on a pre-specified MADRS total score", 
                "measure": "Remission during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "The total time the patient spends in remission during randomised treatment", 
                "measure": "Total time in remission during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "The time until full remission has been obtained", 
                "measure": "Time to full remission during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "CGI-S score", 
                "measure": "Change from randomisation in clinical global impression during the randomised treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "SDS total score", 
                "measure": "Change from randomisation in functionality", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q (SF)) total score", 
                "measure": "Change from randomisation in health-related quality of life", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 36 weeks"
            }, 
            {
                "description": "Number of adverse events", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 weeks and a 4-week safety follow up"
            }, 
            {
                "description": "Columbia-Suicide Severity Rating Scale (C-SSRS) score", 
                "measure": "Risk of suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 weeks"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}